People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Other Health Care, Healthtech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Urotronic, Inc. | — | Other Health Care | Series B | $38.5M | $253.7M | 2018 |
| GIE Medical, Inc. | — | Healthtech | Series A | $18.0M | $34.0M | 2018 |
| Restora Medical, Inc. | — | Biotechnology | Series A | $9.5M | $23.2M | 2025 |
| Optilume Stricture, LLC | — | Other Health Care | Pre-Seed | $954K | $25.8M | 2020 |
Lixiao Wang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lixiao Wang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hui Hu | 3 | 4 |
| David Perry | 2 | 11 |
| Jeff Thomas | 2 | 4 |
| Rushu Luo | 2 | 3 |
| Yuriy Prilutskiy | 2 | 3 |
| Doug Kohrs | 2 | 3 |
| Tan Ching | 2 | 2 |
| Chau Khuong | 1 | 9 |
| Ye Zhang | 1 | 2 |
| Ouyang Xiangyu | 1 | 2 |
| Junfeng Wang | 1 | 1 |
| Tianji Zhu | 1 | 1 |
| Quan Ni | 1 | 1 |
| Ling Shang | 1 | 1 |
| Jafar Wang | 1 | 1 |
| Robert Luo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.